<p>Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events</p>

英夫利昔单抗 医学 银屑病 生物仿制药 不利影响 甲氨蝶呤 肿瘤坏死因子α 免疫学 皮肤病科 内科学
作者
Smriti Subedi,Yu Gong,Youdong Chen,Yuling Shi
出处
期刊:Drug Design Development and Therapy [Dove Medical Press]
卷期号:Volume 13: 2491-2502 被引量:57
标识
DOI:10.2147/dddt.s200147
摘要

Psoriasis is a chronic immune-mediated skin disease affecting multiple systems, and tumor necrosis factor-α (TNF-α) plays a significant role in the initiation and progression of the disease process. Psoriasis has a high prevalence rate in the Western world, especially in the USA and Australia; in China, although the prevalence rate is much lower, there is still a large number of patients suffering from psoriasis and its comorbidities. As TNF-α is thought to be crucial in the pathogenesis of psoriasis, specific therapy blocking TNF-α may be beneficial in the treatment of this disease. Infliximab, a murine-human monoclonal antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis, with better skin clearance and faster onset of action than topical medications such as methotrexate, narrow-band ultraviolet B, and calcipotriol. Lack of adherence to infliximab therapy is mainly due to loss of response (LOR) over time and adverse events, particularly because infusion reactions are usually encountered. Anti-infliximab antibody is thought to be responsible for the LOR and infusion reactions. However, the mechanism underlying the formation of anti-infliximab antibody and its side effects remains unclear. Further studies identifying patients at risk for LOR will probably help clinicians to select the right patients for anti-TNF-α therapy and to increase the durability of the treatment. This review discusses the efficacy of infliximab as demonstrated by various clinical trials, LOR to infliximab, combatting LOR, as well as the adverse events usually faced during the use of infliximab therapy and the infliximab biosimilar Remsima®. We hope that we can discover a better way to use infliximab in the therapy of psoriasis from the current research data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
深情安青应助股价采纳,获得10
2秒前
科目三应助Alexander采纳,获得10
2秒前
Susan111应助DZ采纳,获得10
2秒前
111222发布了新的文献求助10
3秒前
yyl发布了新的文献求助10
4秒前
华仔应助zfg采纳,获得10
4秒前
Yelanjiao发布了新的文献求助10
4秒前
777发布了新的文献求助10
4秒前
5秒前
柒秒发布了新的文献求助20
5秒前
zic123完成签到,获得积分10
5秒前
5秒前
辛慧娟关注了科研通微信公众号
5秒前
一只半夏完成签到,获得积分10
5秒前
5秒前
6秒前
7秒前
7秒前
852应助小洋芋采纳,获得10
7秒前
赘婿应助卜婉君采纳,获得10
8秒前
枫枫枫枫发布了新的文献求助10
9秒前
9秒前
愉快的败发布了新的文献求助10
9秒前
皮汤汤发布了新的文献求助10
10秒前
完美世界应助cslghe采纳,获得10
10秒前
Sisi发布了新的文献求助10
10秒前
千跃发布了新的文献求助10
10秒前
Yelanjiao完成签到,获得积分10
10秒前
alwry发布了新的文献求助10
10秒前
今后应助鱼咬羊采纳,获得10
10秒前
dvjkj关注了科研通微信公众号
10秒前
开心米粉关注了科研通微信公众号
11秒前
11秒前
11秒前
wys发布了新的文献求助20
11秒前
飞涛发布了新的文献求助10
11秒前
科研发布了新的文献求助10
11秒前
怕孤独的修杰完成签到 ,获得积分10
11秒前
彭于晏应助PAD采纳,获得30
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974602
求助须知:如何正确求助?哪些是违规求助? 3519026
关于积分的说明 11196787
捐赠科研通 3255127
什么是DOI,文献DOI怎么找? 1797693
邀请新用户注册赠送积分活动 877100
科研通“疑难数据库(出版商)”最低求助积分说明 806130